There is no English translation for this web page.
The future of pharmaceutical policy in the European Union until 2025 – results of a Delphi survey
|Autor||van Ginneken E,
Pharmaceutical Health Services Research 1: 53-60
- © .
Objectives To examine
expectations of and opinions on the development of European Union (EU)
and national competencies in pharmaceutical policy until 2025.
Methods Key issues of pharmaceutical policy
(authorisation, pharmacovigilance, classification, distribution,
advertising, pricing, dispensing, prescribing, post-licensing
evaluation and reimbursement) were selected from published literature.
Next a two-round Delphi questionnaire was developed in which 41
selected European experts were asked to rate the level of competence
on these issues using a five-point Likert scale (1 = fully national, 5
= fully European). Key findings Experts expect that
authorisation, pharmacovigilance, classification, distribution,
advertising and post-licensing evaluation show a steady and gradual
trend towards European regulation. Pricing, dispensing, prescribing
and reimbursement remain predominantly national competencies.
Conclusions Convergence due to the Europeanisation of
the pharmaceutical market reinforces opportunities for (and in some
cases necessitates) more European collaboration or regulation.
National governments are well advised to support such collaborations
and to actively participate in the direction of future EU policy
instead of resisting it.